Yili Chuanning Biotechnology Co.,Ltd.

SZSE:301301 Stock Report

Market Cap: CN¥27.5b

Yili Chuanning BiotechnologyLtd Past Earnings Performance

Past criteria checks 5/6

Yili Chuanning BiotechnologyLtd has been growing earnings at an average annual rate of 47.4%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 12.9% per year. Yili Chuanning BiotechnologyLtd's return on equity is 18.1%, and it has net margins of 24.2%.

Key information

47.4%

Earnings growth rate

53.0%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate12.9%
Return on equity18.1%
Net Margin24.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely

Oct 11
These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely

If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity

Jul 23
If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity

We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease

May 31
We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease

Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt

Feb 26
Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt

Revenue & Expenses Breakdown

How Yili Chuanning BiotechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:301301 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245,6981,37618960
30 Jun 245,6021,31618360
31 Mar 245,0771,11817658
31 Dec 234,82394117255
30 Sep 234,4627197048
30 Jun 234,2545658441
31 Mar 234,09348613539
01 Jan 233,82141217035
30 Sep 223,63427235059
31 Mar 223,34515417135
01 Jan 223,23211112933
31 Dec 203,64922912325
31 Dec 193,1439117818
31 Dec 183,3493901235

Quality Earnings: 301301 has high quality earnings.

Growing Profit Margin: 301301's current net profit margins (24.2%) are higher than last year (16.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301301's earnings have grown significantly by 47.4% per year over the past 5 years.

Accelerating Growth: 301301's earnings growth over the past year (91.3%) exceeds its 5-year average (47.4% per year).

Earnings vs Industry: 301301 earnings growth over the past year (91.3%) exceeded the Biotechs industry 1.3%.


Return on Equity

High ROE: 301301's Return on Equity (18.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:56
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yili Chuanning Biotechnology Co.,Ltd. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Chao LiCitic Securities Co., Ltd.
Ban WangMinsheng Securities Co.